OBJECTIVES: To assess the frequency of mitochondrial abnormalities in muscle histology, defects in respiratory chain enzyme activities, and mutations in mitochondrial DNA (mtDNA) in children with unexplained psychomotor retardation in the population of Northern Finland. BACKGROUND: The frequency of mitochondrial diseases among patients with childhood encephalopathies and myopathies is not known. Frequencies are difficult to estimate because the clinical presentation of these disorders is variable. METHODS: A total of 116 consecutive patients with undefined encephalopathies and myopathies were enrolled during a 7-year period in a hospital serving as the only neurologic unit for a pediatric population of 97 609 and as the only tertiary level neurologic unit for a pediatric population of 48 873. Biochemical and morphologic investigations were performed on muscle biopsy material, including oximetric and spectrophotometric analyses of oxidative phosphorylation, histochemistry, electron microscopy, and molecular analysis of mtDNA. RESULTS: Ultrastructural changes in the mitochondria were the most common finding in the muscle biopsies (71%). Ragged-red fibers were found in 4 cases. An oxidative phosphorylation defect was found in 26 children (28%), complex I (n = 15) and complex IV (n = 13) defects being the most common. Fifteen percent of patients (n = 17/116) with unexplained encephalomyopathy or myopathy had a probable mitochondrial disease. Common pathogenic mutations were found in the mtDNA of only 1 patient (.9%). CONCLUSIONS: The common known mutations in mtDNA are rarely causes of childhood encephalomyopathies, which is in contrast to the considerable frequency of the common MELAS mutation observed among adults in the same geographical area. Biochemically and morphologically verified mitochondrial disorders were nevertheless common among the children, making the analysis of a muscle biopsy very important for clinical diagnostic purposes.
OBJECTIVES: To assess the frequency of mitochondrial abnormalities in muscle histology, defects in respiratory chain enzyme activities, and mutations in mitochondrial DNA (mtDNA) in children with unexplained psychomotor retardation in the population of Northern Finland. BACKGROUND: The frequency of mitochondrial diseases among patients with childhood encephalopathies and myopathies is not known. Frequencies are difficult to estimate because the clinical presentation of these disorders is variable. METHODS: A total of 116 consecutive patients with undefined encephalopathies and myopathies were enrolled during a 7-year period in a hospital serving as the only neurologic unit for a pediatric population of 97 609 and as the only tertiary level neurologic unit for a pediatric population of 48 873. Biochemical and morphologic investigations were performed on muscle biopsy material, including oximetric and spectrophotometric analyses of oxidative phosphorylation, histochemistry, electron microscopy, and molecular analysis of mtDNA. RESULTS: Ultrastructural changes in the mitochondria were the most common finding in the muscle biopsies (71%). Ragged-red fibers were found in 4 cases. An oxidative phosphorylation defect was found in 26 children (28%), complex I (n = 15) and complex IV (n = 13) defects being the most common. Fifteen percent of patients (n = 17/116) with unexplained encephalomyopathy or myopathy had a probable mitochondrial disease. Common pathogenic mutations were found in the mtDNA of only 1 patient (.9%). CONCLUSIONS: The common known mutations in mtDNA are rarely causes of childhood encephalomyopathies, which is in contrast to the considerable frequency of the common MELAS mutation observed among adults in the same geographical area. Biochemically and morphologically verified mitochondrial disorders were nevertheless common among the children, making the analysis of a muscle biopsy very important for clinical diagnostic purposes.
Authors: Marc Tardieu; Francis Brunelle; Charles Raybaud; William Ball; Béatrice Barret; Brigitte Pautard; Eric Lachassine; Marie-Jeanne Mayaux; Stéphane Blanche Journal: AJNR Am J Neuroradiol Date: 2005-04 Impact factor: 3.825
Authors: Reetta Hinttala; Johanna Uusimaa; Anne M Remes; Heikki Rantala; Ilmo E Hassinen; Kari Majamaa Journal: J Mol Med (Berl) Date: 2005-09-03 Impact factor: 4.599
Authors: Tuomas Komulainen; Milla-Riikka Hautakangas; Reetta Hinttala; Salla Pakanen; Vesa Vähäsarja; Petri Lehenkari; Päivi Olsen; Päivi Vieira; Outi Saarenpää-Heikkilä; Johanna Palmio; Hannu Tuominen; Pietari Kinnunen; Kari Majamaa; Heikki Rantala; Johanna Uusimaa Journal: JIMD Rep Date: 2015-05-05
Authors: Andrea L Ciaranello; George R Seage; Kenneth A Freedberg; Milton C Weinstein; Shahin Lockman; Rochelle P Walensky Journal: AIDS Date: 2008-11-12 Impact factor: 4.177
Authors: K Joost; R J Rodenburg; A Piirsoo; L van den Heuvel; R Zordania; H Põder; I Talvik; K Kilk; U Soomets; K Ounap Journal: Mol Syndromol Date: 2012-07-25
Authors: Michele Jonsson Funk; Suzanne E Belinson; Jeanne M Pimenta; Megan Morsheimer; David C Gibbons Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: M Pronicki; E Matyja; D Piekutowska-Abramczuk; T Szymanska-Debinska; A Karkucinska-Wieckowska; E Karczmarewicz; W Grajkowska; T Kmiec; E Popowska; J Sykut-Cegielska Journal: J Clin Pathol Date: 2007-10-01 Impact factor: 3.411